Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

2.

Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer.

Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X.

Oncol Lett. 2017 Mar;13(3):1949-1957. doi: 10.3892/ol.2017.5616. Epub 2017 Jan 18.

3.

Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial.

Shin YS, Lee JW, Kim MK, Jeong YB, Park SC.

Investig Clin Urol. 2017 Mar;58(2):98-102. doi: 10.4111/icu.2017.58.2.98. Epub 2017 Feb 15.

4.

Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy Gleason score 6.

Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, Chung BH, Choi YD, Rha KH.

Investig Clin Urol. 2017 Mar;58(2):90-97. doi: 10.4111/icu.2017.58.2.90. Epub 2017 Feb 15.

5.

The Genomic Impact of DNA CpG Methylation on Gene Expression; Relationships in Prostate Cancer.

Long MD, Smiraglia DJ, Campbell MJ.

Biomolecules. 2017 Feb 14;7(1). pii: E15. doi: 10.3390/biom7010015. Review.

6.

Comparing Three Data Mining Methods to Predict Kidney Transplant Survival.

Shahmoradi L, Langarizadeh M, Pourmand G, Fard ZA, Borhani A.

Acta Inform Med. 2016 Oct;24(5):322-327. doi: 10.5455/aim.2016.24.322-327. Epub 2016 Nov 1.

7.

Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients.

Patek S, Willder J, Heng J, Taylor B, Horgan P, Leung H, Underwood M, Edwards J.

Oncotarget. 2017 Jan 17;8(3):4875-4887. doi: 10.18632/oncotarget.13608.

8.
9.

Is There Use for FDG-PET in Prostate Cancer?

Jadvar H.

Semin Nucl Med. 2016 Nov;46(6):502-506. doi: 10.1053/j.semnuclmed.2016.07.004. Epub 2016 Sep 3. Review.

PMID:
27825430
10.

PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.

Jadvar H.

J Nucl Med. 2016 Oct;57(Suppl 3):25S-29S. Review.

11.

Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.

Kasuya G, Ishikawa H, Tsuji H, Nomiya T, Makishima H, Kamada T, Akakura K, Suzuki H, Shimazaki J, Haruyama Y, Kobashi G, Tsujii H; Working Group for Genitourinary Tumors.

Cancer. 2016 Oct 15;122(20):3225-3231. doi: 10.1002/cncr.30050. Epub 2016 Jun 28.

12.

Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy.

Ho R, Siddiqui MM, George AK, Frye T, Kilchevsky A, Fascelli M, Shakir NA, Chelluri R, Abboud SF, Walton-Diaz A, Sankineni S, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA.

PLoS One. 2016 Jun 23;11(6):e0157313. doi: 10.1371/journal.pone.0157313. eCollection 2016.

13.

PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.

Kim SH, Park WS, Park BR, Joo J, Joung JY, Seo HK, Chung J, Lee KH.

Asian J Androl. 2017 Jul-Aug;19(4):458-462. doi: 10.4103/1008-682X.180798.

14.
15.

Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Mertan FV, Greer MD, Borofsky S, Kabakus IM, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

Top Magn Reson Imaging. 2016 Jun;25(3):139-47. doi: 10.1097/RMR.0000000000000088. Review.

16.

PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.

Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):223-30. doi: 10.1038/pcan.2016.13. Epub 2016 May 3. Review.

17.

Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.

Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL.

J Urol. 2016 Oct;196(4):1082-9. doi: 10.1016/j.juro.2016.04.069. Epub 2016 Apr 27.

18.

Pelvic Radiotherapy versus Radical Prostatectomy with Limited Lymph Node Sampling for High-Grade Prostate Adenocarcinoma.

Baker CB, McDonald AM, Yang ES, Jacob R, Rais-Bahrami S, Nix JW, Fiveash JB.

Prostate Cancer. 2016;2016:2674954. doi: 10.1155/2016/2674954. Epub 2016 Mar 9.

19.

Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment.

Sanchez A, Schoenfeld JD, Nguyen PL, Fiorentino M, Chowdhury D, Stampfer MJ, Sesso HD, Giovannucci E, Mucci LA, Shui IM.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):197-201. doi: 10.1038/pcan.2016.4. Epub 2016 Mar 1.

Supplemental Content

Support Center